Neeraj Agarwal, MD | Authors

Articles

Previous Trials Inform Toxicity Profile of Cabozantinib/Atezolizumab in mCRPC

March 18, 2021

Neeraj Agarwal, MD, discusses the possible adverse events of the randomized phase 3 CONTACT-02 trial of cabozantinib plus atezolizumab versus a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.